期刊
WIENER KLINISCHE WOCHENSCHRIFT
卷 -, 期 -, 页码 -出版社
SPRINGER WIEN
DOI: 10.1007/s00508-022-02110-2
关键词
Ulcerative colitis; Small molecules; Janus kinase inhibitor; Safety; Effectiveness
资金
- Pfizer
This paper summarizes the mechanism, clinical development, efficacy, and safety of tofacitinib, and aims to optimize its safe and effective use in daily clinical practice.
Ulcerative colitis (UC) is one of the main forms of inflammatory bowel disease (IBD). Despite the widening range of drug treatment options, primary nonresponse, secondary loss of response as well as adverse events call for additional treatment alternatives.Tofacitinib is an oral small-molecule drug of the class of Janus kinase inhibitors which, in the European Union, was approved for the treatment of moderate to severe active UC in August 2018. This position paper, drawn up by the IBD Working Group of the Austrian Society of Gastroenterology and Hepatology, summarizes the mechanism of action, clinical development, marketing authorization status, efficacy and safety of tofacitinib. Also, by providing a synopsis of available data from both pivotal and post-marketing studies, clinical aspects of specific interest are highlighted and discussed.The available body of evidence indicates that tofacitinib is an additional effective medication for the treatment of UC that exhibits a good safety profile. This position paper aims at optimizing the safe and effective use of tofacitinib in daily clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据